Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Treatment decisions and the impact of adverse events before and during extended endocrine therapy in postmenopausal early breast cancer.
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL and TEAM Study Groups. Blok EJ, et al. Eur J Cancer. 2018 May;95:59-67. doi: 10.1016/j.ejca.2018.03.014. Epub 2018 Apr 7. Eur J Cancer. 2018. PMID: 29635145 Clinical Trial.
70-Gene Signature in Early-Stage Breast Cancer.
Blok EJ, van de Velde CJ, Smit VT. Blok EJ, et al. N Engl J Med. 2016 Dec 1;375(22):2199. doi: 10.1056/NEJMc1612048. N Engl J Med. 2016. PMID: 27959763 No abstract available.
Adjuvant tamoxifen and exemestane in women with postmenopausal early breast cancer (TEAM): 10-year follow-up of a multicentre, open-label, randomised, phase 3 trial.
Derks MGM, Blok EJ, Seynaeve C, Nortier JWR, Kranenbarg EM, Liefers GJ, Putter H, Kroep JR, Rea D, Hasenburg A, Markopoulos C, Paridaens R, Smeets JBE, Dirix LY, van de Velde CJH. Derks MGM, et al. Among authors: blok ej. Lancet Oncol. 2017 Sep;18(9):1211-1220. doi: 10.1016/S1470-2045(17)30419-9. Epub 2017 Jul 18. Lancet Oncol. 2017. PMID: 28732650 Clinical Trial.
Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05).
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J, Maartense E, van Leeuwen-Stok AE, Liefers GJ, Nortier JWR, Rutgers EJT, van de Velde CJH; IDEAL Study Group. Blok EJ, et al. J Natl Cancer Inst. 2018 Jan 1;110(1). doi: 10.1093/jnci/djx134. J Natl Cancer Inst. 2018. PMID: 28922787 Clinical Trial.
Relevant factors for the optimal duration of extended endocrine therapy in early breast cancer.
Blok EJ, Kroep JR, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, Liefers GJ, Nortier JWR, Rutgers EJT, Seynaeve CM, van de Velde CJH; IDEAL Study Group. Blok EJ, et al. Breast Cancer Res Treat. 2018 Apr;168(2):413-420. doi: 10.1007/s10549-017-4601-1. Epub 2017 Dec 12. Breast Cancer Res Treat. 2018. PMID: 29230665 Free PMC article. Clinical Trial.
Exploration of tumour-infiltrating lymphocytes as a predictive biomarker for adjuvant endocrine therapy in early breast cancer.
Blok EJ, Engels CC, Dekker-Ensink G, Meershoek-Klein Kranenbarg E, Putter H, Smit VTHBM, Liefers GJ, Morden JP, Bliss JM, Coombes RC, Bartlett JMS, Kroep JR, van de Velde CJH, Kuppen PJK. Blok EJ, et al. Breast Cancer Res Treat. 2018 Aug;171(1):65-74. doi: 10.1007/s10549-018-4785-z. Epub 2018 May 15. Breast Cancer Res Treat. 2018. PMID: 29766362
18 results